Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Lewis Rubin

    TitleEmeritus Professor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9300 Campus Point Drive #7381
    CA La Jolla 92037
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Rubin L. Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension. Eur Respir J. 2017 Sep; 50(3). PMID: 28893872.
        View in: PubMed
      2. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin L, Simonneau G, Sitbon O, Tapson VF, Hoeper MM. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 Aug; 50(2). PMID: 28818881.
        View in: PubMed
      3. Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin L, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017 Apr 14; 38(15):1147-1155. PMID: 28329315.
        View in: PubMed
      4. Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin L. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017 Jul; 76(7):1219-1227. PMID: 28039187.
        View in: PubMed
      5. Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin L, Fritsch A, Davie N, Ghofrani HA. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. J Heart Lung Transplant. 2017 May; 36(5):509-519. PMID: 28190787.
        View in: PubMed
      6. Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galiè N. Future perspectives in pulmonary arterial hypertension. Eur Respir Rev. 2016 Dec; 25(142):381-389. PMID: 27903660.
        View in: PubMed
      7. Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin L, Vachiery JL. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016 Nov; 4(11):894-901. PMID: 27745818.
        View in: PubMed
      8. Mehta S, Sastry BK, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin L, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. Chest. 2017 Jan; 151(1):106-118. PMID: 27671974.
        View in: PubMed
      9. Rubin L. The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: a cautionary tale. Eur Respir J. 2016 Sep; 48(3):617-8. PMID: 27581405.
        View in: PubMed
      10. Ben-Yehuda O, Rubin L. Pulmonary Hypertension Overlap Syndromes: A Real Entity? J Am Coll Cardiol. 2016 Jul 26; 68(4):379-81. PMID: 27443434.
        View in: PubMed
      11. Rubin L. Are Animal Models of Pulmonary Hypertension Relevant to the Clinical Disease? J Am Coll Cardiol. 2016 May 03; 67(17):2047-9. PMID: 27126532.
        View in: PubMed
      12. Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH, Zwicke DL, Feldman JP, Chakinala MM, Frantz RP, Torres F, Cerkvenik J, Morris M, Thalin M, Peterson L, Rubin L. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. Chest. 2016 Jul; 150(1):27-34. PMID: 27396777.
        View in: PubMed
      13. Rubin L. Pulmonary Artery Denervation for Pulmonary Artery Hypertension. JACC Cardiovasc Interv. 2015 Dec 28; 8(15):2024-2025. PMID: 26738674.
        View in: PubMed
      14. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin L, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24; 373(26):2522-33. PMID: 26699168.
        View in: PubMed
      15. Galiè N, McLaughlin VV, Rubin L, Simonneau G. Improving patient outcomes in pulmonary hypertension. Eur Respir Rev. 2015 Dec; 24(138):550-1. PMID: 26621969.
        View in: PubMed
      16. Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin L. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015 Dec; 46(6):1711-20. PMID: 26493786; PMCID: PMC4664609.
      17. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin L. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27; 373(9):834-44. PMID: 26308684.
        View in: PubMed
      18. Vachiery JL, Rubin L. Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning. Eur Respir J. 2015 Aug; 46(2):297-8. PMID: 26232474.
        View in: PubMed
      19. Rubin L. The beta-adrenergic receptor in pulmonary arterial hypertension: a novel therapeutic target? J Am Coll Cardiol. 2015 Feb 24; 65(7):681-3. PMID: 25677429.
        View in: PubMed
      20. Rubin L, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani HA. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015 May; 45(5):1303-13. PMID: 25614164.
        View in: PubMed
      21. Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin L, Zhou D, Curram J, Davie N, Ghofrani HA. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. J Heart Lung Transplant. 2015 Mar; 34(3):338-47. PMID: 25703961.
        View in: PubMed
      22. McLaughlin V, Simonneau G, Galiè N, Rubin L. New horizons in pulmonary arterial hypertension management. Eur Respir Rev. 2014 Dec; 23(134):408-9. PMID: 25445938.
        View in: PubMed
      23. Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin L, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015 Jan; 3(1):1-8. PMID: 25457902.
        View in: PubMed
      24. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin L, Sandoval J, Seeger W, Keogh A. [Updated treatment algorithm of pulmonary arterial hypertension]. Turk Kardiyol Dern Ars. 2014 Oct; 42 Suppl 1:78-94. PMID: 25697036.
        View in: PubMed
      25. Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin L. [New trial designs and potential therapies for pulmonary artery hypertension]. Turk Kardiyol Dern Ars. 2014 Oct; 42 Suppl 1:106-18. PMID: 25697038.
        View in: PubMed
      26. Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin L. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med. 2014 Jul; 2(7):573-82. PMID: 24898750.
        View in: PubMed
      27. Simonneau G, Rubin L, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 Jul; 33(7):689-97. PMID: 24815795.
        View in: PubMed
      28. Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin L. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014 Mar 15; 172(2):332-9. PMID: 24525158.
        View in: PubMed
      29. Pulido T, Rubin L, Simonneau G. Macitentan and pulmonary arterial hypertension. N Engl J Med. 2014 Jan 02; 370(1):82-3. PMID: 24382071.
        View in: PubMed
      30. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin L, Sandoval J, Seeger W, Keogh A. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D60-72. PMID: 24355643.
        View in: PubMed
      31. Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin L. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D82-91. PMID: 24355645; PMCID: PMC4117578.
      32. Ghofrani HA, Simonneau G, Rubin L. Riociguat for pulmonary hypertension. N Engl J Med. 2013 Dec 05; 369(23):2268. PMID: 24304056.
        View in: PubMed
      33. Rubin L, Galiè N, Simonneau G, McLaughlin V. A paradigm shift in pulmonary arterial hypertension management. Eur Respir Rev. 2013 Dec; 22(130):423-6. PMID: 24293459.
        View in: PubMed
      34. Dingemanse J, Sidharta PN, Maddrey WC, Rubin L, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2014 Mar; 13(3):391-405. PMID: 24261583.
        View in: PubMed
      35. Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin L, McLaughlin V. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014 Feb; 167(2):218-225.e1. PMID: 24439983.
        View in: PubMed
      36. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin L, Simonneau G. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29; 369(9):809-18. PMID: 23984728.
        View in: PubMed
      37. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin L. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25; 369(4):330-40. PMID: 23883378.
        View in: PubMed
      38. Rubin L. Cor pulmonale revisited. J Am Coll Cardiol. 2013 Sep 17; 62(12):1112-3. PMID: 23850928.
        View in: PubMed
      39. Rubin L. Robyn J. Barst, MD. Eur Respir J. 2013 Jul; 42(1):16-7. PMID: 23971081.
        View in: PubMed
      40. Rubin L. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT. Circulation. 2013 Jul 30; 128(5):475-6. PMID: 23775259.
        View in: PubMed
      41. Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro S, White RJ, McSwain CS, Gotzkowsky SK, Nelsen AC, Rubin L. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther. 2013 Feb; 31(1):38-44. PMID: 22970909; PMCID: PMC3561685.
      42. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin L. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013 Feb 05; 127(5):624-33. PMID: 23307827.
        View in: PubMed
      43. Torres F, Rubin L. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013 Jan; 11(1):13-25. PMID: 23259441.
        View in: PubMed
      44. Rubin L. Pulmonary hypertension: current management and future directions. Handb Exp Pharmacol. 2013; 218:551-5. PMID: 24092355.
        View in: PubMed
      45. Humbert M, Souza R, Galiè N, McLaughlin V, Simonneau G, Rubin L. Pulmonary arterial hypertension: bridging the present to the future. Eur Respir Rev. 2012 Dec 01; 21(126):267-70. PMID: 23204116.
        View in: PubMed
      46. Galiè N, Rubin L, Simonneau G. Developing a heart score: next steps. Am J Cardiol. 2012 Sep 15; 110(6 Suppl):49S-51S. PMID: 22921032.
        View in: PubMed
      47. Rubin L. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? Am J Respir Crit Care Med. 2012 Sep 01; 186(5):396-7. PMID: 22942342.
        View in: PubMed
      48. Rubin L, Simonneau G, Badesch D, Galiè N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O, Kymes S. The study of risk in pulmonary arterial hypertension. Eur Respir Rev. 2012 Sep 01; 21(125):234-8. PMID: 22941888.
        View in: PubMed
      49. Kohan DE, Cleland JG, Rubin L, Theodorescu D, Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 2012 Oct 15; 91(13-14):528-39. PMID: 22967485.
        View in: PubMed
      50. Vizza CD, Fedele F, Pezzuto B, Rubin L. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf. 2012 Nov; 11(6):1003-11. PMID: 22861496.
        View in: PubMed
      51. Rubin L. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci. 2012 Oct 15; 91(13-14):517-21. PMID: 22884806.
        View in: PubMed
      52. de Jesus Perez VA, Rosenzweig E, Rubin L, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol. 2012 Nov 15; 110(10):1546-50. PMID: 22853986.
        View in: PubMed
      53. Rubin L. Exercise training for pulmonary hypertension: another prescription to write? Eur Respir J. 2012 Jul; 40(1):7-8. PMID: 22753832.
        View in: PubMed
      54. Channick RN, Voswinckel R, Rubin L. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther. 2012; 6:19-28. PMID: 22291467; PMCID: PMC3267519.
      55. Rubin L. Combination therapy for pulmonary artery hypertension: what is the evidence? Cardiology. 2011; 120(3):172-3. PMID: 22248863.
        View in: PubMed
      56. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin L. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011 Dec; 30(12):1327-33. PMID: 22055098.
        View in: PubMed
      57. Humbert M, Simonneau G, Rubin L. A decade of achievement in pulmonary hypertension. Eur Respir Rev. 2011 Dec; 20(122):215-7. PMID: 22130812.
        View in: PubMed
      58. Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, Scheidl S, Tröster N, Hesse C, Rubin L, Olschewski H. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum. 2012 Apr; 64(4):1257-62. PMID: 22127844.
        View in: PubMed
      59. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin L, Langer A. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012 Feb; 71(2):249-52. PMID: 21998119.
        View in: PubMed
      60. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin L, Seibold JR, Strand V, Furst DE, Distler O. Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2011 Nov; 38(11):2419-27. PMID: 21965635.
        View in: PubMed
      61. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin L. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9. PMID: 21884013.
        View in: PubMed
      62. Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, Matucci-Cerinic M, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Distler O. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Res Ther. 2011 Jun 20; 13(3):114. PMID: 21699746; PMCID: PMC3218892.
      63. Rubin L, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011 Nov; 140(5):1274-1283. PMID: 21546436.
        View in: PubMed
      64. Rubin L, Morrell NW. New frontiers in pulmonary hypertension. Expert Rev Respir Med. 2011 Apr; 5(2):139-40. PMID: 21510723.
        View in: PubMed
      65. Rubin L. Metabolic dysfunction in the pathogenesis of pulmonary hypertension. Cell Metab. 2010 Oct 06; 12(4):313-4. PMID: 20889122.
        View in: PubMed
      66. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin L, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010 Jul; 62(7):2101-8. PMID: 20506355.
        View in: PubMed
      67. Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin L, Seibold JR, Strand V, Furst DE. Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clin Exp Rheumatol. 2010 Mar-Apr; 28(2 Suppl 58):S47-52. PMID: 20576214.
        View in: PubMed
      68. Elliott CG, Barst RJ, Seeger W, Porres-Aguilar M, Brown LM, Zamanian RT, Rubin L. Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest. 2010 Jun; 137(6 Suppl):85S-94S. PMID: 20522584.
        View in: PubMed
      69. Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin L, Seibold JR, Distler O, Furst DE. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis. 2010 Jul; 69(7):1360-3. PMID: 20472586.
        View in: PubMed
      70. McLaughlin VV, Benza RL, Rubin L, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010 May 04; 55(18):1915-22. PMID: 20430262.
        View in: PubMed
      71. Galiè N, Simonneau G, Barst RJ, Badesch D, Rubin L. Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med. 2010 May; 16 Suppl 1:S11-9. PMID: 20375660.
        View in: PubMed
      72. Rubin L, Simonneau G. Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Curr Opin Pulm Med. 2010 May; 16 Suppl 1:S43-6. PMID: 20375664.
        View in: PubMed
      73. Park MH, Rubin L. Editor's response to "ethical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertension". J Heart Lung Transplant. 2010 Jul; 29(7):827-8. PMID: 20417131.
        View in: PubMed
      74. Fine DM, Durham HE, Rossi NF, Spier AW, Selting K, Rubin L. Echocardiographic assessment of hemodynamic changes produced by two methods of inducing fluid deficit in dogs. J Vet Intern Med. 2010 Mar-Apr; 24(2):348-53. PMID: 20051004.
        View in: PubMed
      75. Galiè N, Rubin L, Simonneau G. Phosphodiesterase inhibitors for pulmonary hypertension. N Engl J Med. 2010 Feb 11; 362(6):559-60; author reply 560. PMID: 20175298.
        View in: PubMed
      76. Park MH, Rubin L. The globalization of clinical trials in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb; 29(2):157-8. PMID: 20113908.
        View in: PubMed
      77. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin L, Seibold JR, Strand V, Furst DE, Distler O. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol. 2010 Jan; 37(1):105-15. PMID: 19955042.
        View in: PubMed
      78. Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin L. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Nov 17; 54(21):1971-81. PMID: 19909879.
        View in: PubMed
      79. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foeldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, Matucci-Cerinic M, Mayes M, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Steen V, Strand CV, Tugwell PS, Varga J, Zink A, Furst DE. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2009 Oct; 36(10):2356-61. PMID: 19820225.
        View in: PubMed
      80. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009 Dec; 34(6):1219-63. PMID: 19749199.
        View in: PubMed
      81. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin L, Wigley FM, Kral KM, Raphiou IH, Crater GD. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009 Oct; 36(10):2244-9. PMID: 19723905.
        View in: PubMed
      82. Humbert M, Rubin L. Combining evidence and experience in pulmonary hypertension. Eur Respir Rev. 2009 Sep; 18(113):135-6. PMID: 20956133.
        View in: PubMed
      83. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct; 30(20):2493-537. PMID: 19713419.
        View in: PubMed
      84. Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Tröster N, Hesse C, Salmhofer W, Graninger W, Gruenig E, Rubin L, Olschewski H. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med. 2009 Nov 01; 180(9):881-6. PMID: 19679693.
        View in: PubMed
      85. Adamali H, Gaine SP, Rubin L. Medical treatment of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009 Aug; 30(4):484-92. PMID: 19634087.
        View in: PubMed
      86. Peacock AJ, Naeije R, Galiè N, Rubin L. End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur Respir J. 2009 Jul; 34(1):231-42. PMID: 19567606.
        View in: PubMed
      87. Ghofrani HA, Barst RJ, Benza RL, Champion HC, Fagan KA, Grimminger F, Humbert M, Simonneau G, Stewart DJ, Ventura C, Rubin L. Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S108-17. PMID: 19555854; PMCID: PMC4883573.
      88. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin L, Sitbon O, Tapson VF, Galiè N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S78-84. PMID: 19555861; PMCID: PMC3686287.
      89. Opitz CF, Rubin L. Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer? Eur Respir J. 2009 Jun; 33(6):1247-9. PMID: 19483043.
        View in: PubMed
      90. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin L, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53(17):1573-619. PMID: 19389575.
        View in: PubMed
      91. Yu Y, Keller SH, Remillard CV, Safrina O, Nicholson A, Zhang SL, Jiang W, Vangala N, Landsberg JW, Wang JY, Thistlethwaite PA, Channick RN, Robbins IM, Loyd JE, Ghofrani HA, Grimminger F, Schermuly RT, Cahalan MD, Rubin L, Yuan JX. A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation. 2009 May 05; 119(17):2313-22. PMID: 19380626; PMCID: PMC2749566.
      92. Rubin L. Endothelin and the systemic circulation a therapeutic target worth revisiting? J Am Coll Cardiol. 2009 Apr 14; 53(15):1318-9. PMID: 19358947.
        View in: PubMed
      93. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin L, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28; 119(16):2250-94. PMID: 19332472.
        View in: PubMed
      94. Yao W, Firth AL, Sacks RS, Ogawa A, Auger WR, Fedullo PF, Madani MM, Lin GY, Sakakibara N, Thistlethwaite PA, Jamieson SW, Rubin L, Yuan JX. Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009 Jun; 296(6):L870-8. PMID: 19286928; PMCID: PMC2692803.
      95. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin L. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008 Dec 16; 52(25):2127-34. PMID: 19095129.
        View in: PubMed
      96. Voswinckel R, Reichenberger F, Gall H, Schmehl T, Gessler T, Schermuly RT, Grimminger F, Rubin L, Seeger W, Ghofrani HA, Olschewski H. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2009 Feb; 22(1):50-6. PMID: 19071225.
        View in: PubMed
      97. Oudiz RJ, Rubin L. Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases. Circulation. 2008 Nov 18; 118(21):2120-1. PMID: 19015412.
        View in: PubMed
      98. Simonneau G, Rubin L, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 Oct 21; 149(8):521-30. PMID: 18936500.
        View in: PubMed
      99. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin L. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009 Jan; 135(1):122-129. PMID: 18812445.
        View in: PubMed
      100. Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin L. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest. 2009 Jan; 135(1):130-136. PMID: 18719056.
        View in: PubMed
      101. Ogawa A, Firth AL, Yao W, Rubin L, Yuan JX. Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2008 Oct; 295(4):L648-57. PMID: 18708631; PMCID: PMC2575943.
      102. Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming TR, Naeije R. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. 2008 Oct; 134(4):775-82. PMID: 18625676.
        View in: PubMed
      103. Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin L, Olschewski H, Seeger W, Ghofrani HA. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther. 2008 Oct; 21(5):824-32. PMID: 18657627.
        View in: PubMed
      104. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin L, Seibold JR, Furst DE. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum. 2008 Jun 15; 59(6):867-75. PMID: 18512721.
        View in: PubMed
      105. Rubin L. BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients. Am J Respir Crit Care Med. 2008 Jun 15; 177(12):1300-1. PMID: 18522952.
        View in: PubMed
      106. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin L. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10; 117(23):3010-9. PMID: 18506008.
        View in: PubMed
      107. Chin KM, Rubin L. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008 Apr 22; 51(16):1527-38. PMID: 18420094.
        View in: PubMed
      108. Rubin L. Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future. Rheum Dis Clin North Am. 2008 Feb; 34(1):191-7; viii. PMID: 18329540.
        View in: PubMed
      109. Badesch DB, Hill NS, Burgess G, Rubin L, Barst RJ, Galiè N, Simonneau G. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 Dec; 34(12):2417-22. PMID: 17985403.
        View in: PubMed
      110. Chin KM, Channick RN, Kim NH, Rubin L. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. Chest. 2007 Sep; 132(3):786-92. PMID: 17646224.
        View in: PubMed
      111. Badesch DB, Abman SH, Simonneau G, Rubin L, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007 Jun; 131(6):1917-28. PMID: 17565025.
        View in: PubMed
      112. Anthi A, Machado RF, Jison ML, Taveira-Dasilva AM, Rubin L, Hunter L, Hunter CJ, Coles W, Nichols J, Avila NA, Sachdev V, Chen CC, Gladwin MT. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007 Jun 15; 175(12):1272-9. PMID: 17379852; PMCID: PMC2176091.
      113. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin L, O'connor DT, Yuan JX. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2007 May; 292(5):C1837-53. PMID: 17267549.
        View in: PubMed
      114. Rubin L, Black CM, Denton CP, Seibold JR. Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. Arthritis Res Ther. 2007; 9 Suppl 2:S10. PMID: 17767739; PMCID: PMC2072884.
      115. Zhang S, Dong H, Rubin L, Yuan JX. Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2007 Jun; 292(6):C2297-305. PMID: 17192285.
        View in: PubMed
      116. Chin KM, Channick RN, Rubin L. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec; 130(6):1657-63. PMID: 17166979.
        View in: PubMed
      117. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin L. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006 Dec 19; 48(12):2546-52. PMID: 17174196.
        View in: PubMed
      118. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin L, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006 Oct 24; 114(17):1883-91. PMID: 17060398.
        View in: PubMed
      119. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, Gall H, Gessler T, Schmehl T, Ghofrani HA, Schermuly RT, Grimminger F, Rubin L, Seeger W, Olschewski H. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006 Oct 17; 48(8):1672-81. PMID: 17045906.
        View in: PubMed
      120. Rubin L. Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target? Circulation. 2006 Sep 26; 114(13):1350-1. PMID: 17000920.
        View in: PubMed
      121. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin L. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006 Oct 03; 48(7):1433-7. PMID: 17010807.
        View in: PubMed
      122. Rubin L, Hoeper MM, Klepetko W, Galiè N, Lang IM, Simonneau G. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc. 2006 Sep; 3(7):601-7. PMID: 16963541.
        View in: PubMed
      123. Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006 Sep; 3(7):608-14. PMID: 16963542.
        View in: PubMed
      124. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin L, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006 Sep; 152(3):521-6. PMID: 16923424.
        View in: PubMed
      125. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin L. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 Dec 01; 174(11):1257-63. PMID: 16946127.
        View in: PubMed
      126. Distler O, Behrens F, Huscher D, Foeldvari I, Zink A, Nash P, Denton CP, Humbert M, Matucci-Cerinic M, Seibold J, Rubin L, Furst DE. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology (Oxford). 2006 Dec; 45(12):1455-7. PMID: 16920751.
        View in: PubMed
      127. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin L. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006 Dec; 28(6):1195-203. PMID: 16899485.
        View in: PubMed
      128. Buch MH, Denton CP, Furst DE, Guillevin L, Rubin L, Wells AU, Matucci-Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM, Seibold JR. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis. 2007 Feb; 66(2):169-73. PMID: 16868020; PMCID: PMC1798506.
      129. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006 Oct; 65(10):1336-40. PMID: 16793845; PMCID: PMC1798307.
      130. Hoeper MM, Mayer E, Simonneau G, Rubin L. Chronic thromboembolic pulmonary hypertension. Circulation. 2006 Apr 25; 113(16):2011-20. PMID: 16636189.
        View in: PubMed
      131. Hoeper MM, Rubin L. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med. 2006 Mar 01; 173(5):499-505. PMID: 16493163.
        View in: PubMed
      132. Rubin L. Pulmonary arterial hypertension. Proc Am Thorac Soc. 2006; 3(1):111-5. PMID: 16493158.
        View in: PubMed
      133. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin L, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17; 353(20):2148-57. PMID: 16291984.
        View in: PubMed
      134. de Jong PA, Lindblad A, Rubin L, Hop WC, de Jongste JC, Brink M, Tiddens HA. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax. 2006 Jan; 61(1):80-5. PMID: 16244089; PMCID: PMC2080716.
      135. Laving A, Khanna A, Rubin L, Ing F, Dohil R, Lavine JE. Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol. J Pediatr Gastroenterol Nutr. 2005 Oct; 41(4):466-8. PMID: 16205516.
        View in: PubMed
      136. Lee SH, Rubin L. Current treatment strategies for pulmonary arterial hypertension. J Intern Med. 2005 Sep; 258(3):199-215. PMID: 16115293.
        View in: PubMed
      137. Hsu HH, Rubin L. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2005 Sep; 6(11):1921-30. PMID: 16144511.
        View in: PubMed
      138. Kim NH, Rubin L. Management following pulmonary thromboendarterectomy: experience versus evidence. Crit Care Med. 2005 Sep; 33(9):2132-3. PMID: 16148499.
        View in: PubMed
      139. Rubin L, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005 Aug 16; 143(4):282-92. PMID: 16103472.
        View in: PubMed
      140. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin L. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Aug 02; 46(3):529-35. PMID: 16053970.
        View in: PubMed
      141. Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin L, Simonneau G. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005 Dec; 60(12):1025-30. PMID: 16055621; PMCID: PMC1747276.
      142. Rubin L, Dufton C, Gerber MJ. Ambrisentan for pulmonary arterial hypertension. Future Cardiol. 2005 Jul; 1(4):425-32. PMID: 19804142.
        View in: PubMed
      143. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin L, Simonneau G. [Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. Rev Esp Cardiol. 2005 May; 58(5):523-66. PMID: 15899198.
        View in: PubMed
      144. Rubin L. Epoprostenol and nesiritide in pulmonary hypertension. Chest. 2005 May; 127(5):1870. PMID: 15888882.
        View in: PubMed
      145. Yuan JX, Rubin L. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation. 2005 Feb 08; 111(5):534-8. PMID: 15699271.
        View in: PubMed
      146. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin L. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005 Feb; 25(2):244-9. PMID: 15684287.
        View in: PubMed
      147. Chin KM, Kim NH, Rubin L. The right ventricle in pulmonary hypertension. Coron Artery Dis. 2005 Feb; 16(1):13-8. PMID: 15654194.
        View in: PubMed
      148. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin L, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 Dec; 25(24):2243-78. PMID: 15589643.
        View in: PubMed
      149. Rubin L, Magliola L, Feng X, Jones AW, Hale CC. Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol (1985). 2005 Jan; 98(1):296-306. PMID: 15377643.
        View in: PubMed
      150. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin L, Yuan JX. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2004 Sep 21; 101(38):13861-6. PMID: 15358862; PMCID: PMC518765.
      151. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin L, Horn EM, Manes A, Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004 Sep; 24(3):353-9. PMID: 15358690.
        View in: PubMed
      152. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin L, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res. 2004 Sep; 68(2):75-103. PMID: 15313118.
        View in: PubMed
      153. Kunichika N, Landsberg JW, Yu Y, Kunichika H, Thistlethwaite PA, Rubin L, Yuan JX. Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. Am J Respir Crit Care Med. 2004 Nov 15; 170(10):1101-7. PMID: 15317671.
        View in: PubMed
      154. Rubin L, Naeije R. Sildenafil for enhanced performance at high altitude? Ann Intern Med. 2004 Aug 03; 141(3):233-5. PMID: 15289224.
        View in: PubMed
      155. Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin L, Simonneau G. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004 Aug; 126(2):420-7. PMID: 15302727.
        View in: PubMed
      156. Bowles DK, Maddali KK, Ganjam VK, Rubin L, Tharp DL, Turk JR, Heaps CL. Endogenous testosterone increases L-type Ca2+ channel expression in porcine coronary smooth muscle. Am J Physiol Heart Circ Physiol. 2004 Nov; 287(5):H2091-8. PMID: 15242831.
        View in: PubMed
      157. Rubin L. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl):4S-6S. PMID: 15249490.
        View in: PubMed
      158. Rubin L. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl):7S-10S. PMID: 15249491.
        View in: PubMed
      159. Elliott CG, Rubin L. Mars or venus--is sex a risk factor for recurrent venous thromboembolism? N Engl J Med. 2004 Jun 17; 350(25):2614-6. PMID: 15201419.
        View in: PubMed
      160. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin L. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):62S-67S. PMID: 15194180.
        View in: PubMed
      161. Simonneau G, Galiè N, Rubin L, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):5S-12S. PMID: 15194173.
        View in: PubMed
      162. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin L. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):81S-88S. PMID: 15194183.
        View in: PubMed
      163. Rubin L, Galiè N. Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):89S-90S. PMID: 15194184.
        View in: PubMed
      164. Franke R, Yang Y, Rubin L, Magliola L, Jones AW. High-fat diet alters K+-currents in porcine coronary arteries and adenosine sensitivity during metabolic inhibition. J Cardiovasc Pharmacol. 2004 Apr; 43(4):495-503. PMID: 15085060.
        View in: PubMed
      165. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, Jamieson SW, Rubin L. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004 Apr; 23(4):595-600. PMID: 15083760.
        View in: PubMed
      166. Kim NH, Fesler P, Channick RN, Knowlton KU, Ben-Yehuda O, Lee SH, Naeije R, Rubin L. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation. 2004 Jan 06; 109(1):18-22. PMID: 14699009.
        View in: PubMed
      167. Kim NH, Channick RN, Rubin L. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest. 2003 Oct; 124(4):1612-5. PMID: 14555600.
        View in: PubMed
      168. Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, Kneussl M, Rubin L, Kyrle PA, Klepetko W, Maurer G, Lang IM. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2003 Sep; 90(3):372-6. PMID: 12958604.
        View in: PubMed
      169. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin L. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003 Jul; 124(1):247-54. PMID: 12853530.
        View in: PubMed
      170. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Jun 18; 41(12):2119-25. PMID: 12821234.
        View in: PubMed
      171. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin L, Yuan JX. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003 Sep; 285(3):L740-54. PMID: 12740218.
        View in: PubMed
      172. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Apr 16; 41(8):1380-6. PMID: 12706935.
        View in: PubMed
      173. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin L, Rich S. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003 Feb; 41(2):293-9. PMID: 12548091.
        View in: PubMed
      174. Kerr KM, Rubin L. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Chest. 2003 Feb; 123(2):319-20. PMID: 12576339.
        View in: PubMed
      175. Fesler P, Pagnamenta A, Vachiéry JL, Brimioulle S, Abdel Kafi S, Boonstra A, Delcroix M, Channick RN, Rubin L, Naeije R. Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J. 2003 Jan; 21(1):31-6. PMID: 12570105.
        View in: PubMed
      176. Rubin L. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med. 2002 Nov 15; 166(10):1308-9. PMID: 12421739.
        View in: PubMed
      177. Williamson TL, Kim NH, Rubin L. Chronic thromboembolic pulmonary hypertension. Prog Cardiovasc Dis. 2002 Nov-Dec; 45(3):203-12. PMID: 12525996.
        View in: PubMed
      178. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin L, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 01; 347(5):322-9. PMID: 12151469.
        View in: PubMed
      179. Rubin L, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs. 2002 Jul; 11(7):991-1002. PMID: 12084009.
        View in: PubMed
      180. Hoeper MM, Galiè N, Simonneau G, Rubin L. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002 May 01; 165(9):1209-16. PMID: 11991870.
        View in: PubMed
      181. Rubin L, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21; 346(12):896-903. PMID: 11907289.
        View in: PubMed
      182. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin L. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15; 165(6):800-4. PMID: 11897647.
        View in: PubMed
      183. Clapp LH, Finney P, Turcato S, Tran S, Rubin L, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002 Feb; 26(2):194-201. PMID: 11804870.
        View in: PubMed
      184. Kim NH, Rubin L. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther. 2002 Jan; 7(1):9-19. PMID: 12000973.
        View in: PubMed
      185. Krick S, Platoshyn O, Sweeney M, McDaniel SS, Zhang S, Rubin L, Yuan JX. Nitric oxide induces apoptosis by activating K+ channels in pulmonary vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2002 Jan; 282(1):H184-93. PMID: 11748062.
        View in: PubMed
      186. Fedullo PF, Auger WR, Kerr KM, Rubin L. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001 Nov 15; 345(20):1465-72. PMID: 11794196.
        View in: PubMed
      187. Robbins IM, Barst RJ, Rubin L, Gaine SP, Price PV, Morrow JD, Christman BW. Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension. Chest. 2001 Nov; 120(5):1639-44. PMID: 11713147.
        View in: PubMed
      188. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin L. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001 Oct 06; 358(9288):1119-23. PMID: 11597664.
        View in: PubMed
      189. Robbins IM, Barst RJ, Channick RN, Rubin L. Pulmonary vasoreactivity in PPH. J Am Coll Cardiol. 2001 Oct; 38(4):1267-8. PMID: 11587028.
        View in: PubMed
      190. Krick S, Platoshyn O, McDaniel SS, Rubin L, Yuan JX. Augmented K(+) currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. Am J Physiol Lung Cell Mol Physiol. 2001 Oct; 281(4):L887-94. PMID: 11557592.
        View in: PubMed
      191. Yu Y, Platoshyn O, Zhang J, Krick S, Zhao Y, Rubin L, Rothman A, Yuan JX. c-Jun decreases voltage-gated K(+) channel activity in pulmonary artery smooth muscle cells. Circulation. 2001 Sep 25; 104(13):1557-63. PMID: 11571252.
        View in: PubMed
      192. Channick RN, Rubin L. New and experimental therapies for pulmonary hypertension. Clin Chest Med. 2001 Sep; 22(3):539-45. PMID: 11590847.
        View in: PubMed
      193. Fedullo PF, Auger WR, Channick RN, Kerr KM, Rubin L. Chronic thromboembolic pulmonary hypertension. Clin Chest Med. 2001 Sep; 22(3):561-81. PMID: 11590849.
        View in: PubMed
      194. Limsuwan A, Platoshyn O, Yu Y, Rubin L, Rothman A, Yuan JX. Inhibition of K(+) channel activity in human pulmonary artery smooth muscle cells by serum from patients with pulmonary hypertension secondary to congenital heart disease. Pediatr Res. 2001 Jul; 50(1):23-8. PMID: 11420414.
        View in: PubMed
      195. Dhalla AK, Dodam JR, Jones AW, Rubin L. Characterization of an NBTI-sensitive equilibrative nucleoside transporter in vascular smooth muscle. J Mol Cell Cardiol. 2001 Jun; 33(6):1143-52. PMID: 11444919.
        View in: PubMed
      196. McDaniel SS, Platoshyn O, Wang J, Yu Y, Sweeney M, Krick S, Rubin L, Yuan JX. Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 2001 May; 280(5):L870-80. PMID: 11290510.
        View in: PubMed
      197. Rubin L. Therapy of pulmonary hypertension: targeting pathogenic mechanisms with selective treatment delivery. Crit Care Med. 2001 May; 29(5):1086-7. PMID: 11378627.
        View in: PubMed
      198. Platoshyn O, Yu Y, Golovina VA, McDaniel SS, Krick S, Li L, Wang JY, Rubin L, Yuan JX. Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes. Am J Physiol Lung Cell Mol Physiol. 2001 Apr; 280(4):L801-12. PMID: 11238022.
        View in: PubMed
      199. Bailey CL, Channick RN, Rubin L. A new era in the treatment of primary pulmonary hypertension. Heart. 2001 Mar; 85(3):251-2. PMID: 11179256; PMCID: PMC1729642.
      200. Golovina VA, Platoshyn O, Bailey CL, Wang J, Limsuwan A, Sweeney M, Rubin L, Yuan JX. Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol. 2001 Feb; 280(2):H746-55. PMID: 11158974.
        View in: PubMed
      201. Channick R, Badesch DB, Tapson VF, Simonneau G, Robbins I, Frost A, Roux S, Rainisio M, Bodin F, Rubin L. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant. 2001 Feb; 20(2):262-263. PMID: 11250530.
        View in: PubMed
      202. Yung GL, Rubin L. Approach to pulmonary hypertension. Curr Rheumatol Rep. 2000 Dec; 2(6):517-23. PMID: 11123107.
        View in: PubMed
      203. Bailey CL, Channick RN, Auger WR, Fedullo PF, Kerr KM, Yung GL, Rubin L. "High probability" perfusion lung scans in pulmonary venoocclusive disease. Am J Respir Crit Care Med. 2000 Nov; 162(5):1974-8. PMID: 11069842.
        View in: PubMed
      204. Platoshyn O, Golovina VA, Bailey CL, Limsuwan A, Krick S, Juhaszova M, Seiden JE, Rubin L, Yuan JX. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol Cell Physiol. 2000 Nov; 279(5):C1540-9. PMID: 11029301.
        View in: PubMed
      205. Gaine SP, Rubin L, Kmetzo JJ, Palevsky HI, Traill TA. Recreational use of aminorex and pulmonary hypertension. Chest. 2000 Nov; 118(5):1496-7. PMID: 11083709.
        View in: PubMed
      206. Rubin L, Johnson LR, Dodam JR, Dhalla AK, Magliola L, Laughlin MH, Jones AW. Selective transport of adenosine into porcine coronary smooth muscle. Am J Physiol Heart Circ Physiol. 2000 Sep; 279(3):H1397-410. PMID: 10993808.
        View in: PubMed
      207. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin L, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21; 132(6):425-34. PMID: 10733441.
        View in: PubMed
      208. Lilienfeld DE, Rubin L. Mortality from primary pulmonary hypertension in the United States, 1979-1996. Chest. 2000 Mar; 117(3):796-800. PMID: 10713009.
        View in: PubMed
      209. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000 Mar; 117(3):870-4. PMID: 10713017.
        View in: PubMed
      210. Channick RN, Rubin L. Combination therapy for pulmonary hypertension: a glimpse into the future? Crit Care Med. 2000 Mar; 28(3):896-7. PMID: 10752856.
        View in: PubMed
      211. Fedullo PF, Rubin L, Kerr KM, Auger WR, Channick RN. The natural history of acute and chronic thromboembolic disease: the search for the missing link. Eur Respir J. 2000 Mar; 15(3):435-7. PMID: 10759432.
        View in: PubMed
      212. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin L, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000 Jan; 117(1):14-8. PMID: 10631192.
        View in: PubMed
      213. Bakst AE, Gaine SP, Rubin L. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease. Chest. 1999 Oct; 116(4):1127-9. PMID: 10531185.
        View in: PubMed
      214. Jones AW, Rubin L, Magliola L. Endothelin-1 sensitivity of porcine coronary arteries is reduced by exercise training and is gender dependent. J Appl Physiol (1985). 1999 Sep; 87(3):1172-7. PMID: 10484592.
        View in: PubMed
      215. Soriano CM, Gaine SP, Conte JV, Fairman RP, White C, Rubin L. Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction. Chest. 1999 Aug; 116(2):564-6. PMID: 10453890.
        View in: PubMed
      216. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin L, Johnson LB. Portopulmonary hypertension and the liver transplant candidate. Transplantation. 1999 Apr 27; 67(8):1087-93. PMID: 10232556.
        View in: PubMed
      217. Rubin L. Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatr Pulmonol Suppl. 1999; 18:194-7. PMID: 10093141.
        View in: PubMed
      218. Newkirk MM, LePage K, Niwa T, Rubin L. Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cell Mol Biol (Noisy-le-grand). 1998 Nov; 44(7):1129-38. PMID: 9846895.
        View in: PubMed
      219. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV, Gaine SP, Orens JB, Rubin L. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 1998 Oct 06; 98(14):1400-6. PMID: 9760294.
        View in: PubMed
      220. Gilbert TB, Gaine SP, Rubin L, Sequeira AJ. Short-term outcome and predictors of adverse events following pulmonary thromboendarterectomy. World J Surg. 1998 Oct; 22(10):1029-32; discussion 1033. PMID: 9747161.
        View in: PubMed
      221. Gaine SP, Rubin L. Primary pulmonary hypertension. Lancet. 1998 Aug 29; 352(9129):719-25. PMID: 9729004.
        View in: PubMed
      222. Wang J, Juhaszova M, Conte JV, Gaine SP, Rubin L, Yuan JX. Action of fenfluramine on voltage-gated K+ channels in human pulmonary-artery smooth-muscle cells. Lancet. 1998 Jul 25; 352(9124):290. PMID: 9690417.
        View in: PubMed
      223. Conte JV, Gaine SP, Orens JB, Harris T, Rubin L. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant. 1998 Jul; 17(7):679-85. PMID: 9703232.
        View in: PubMed
      224. Esch F, Lin KI, Hills A, Zaman K, Baraban JM, Chatterjee S, Rubin L, Ash DE, Ratan RR. Purification of a multipotent antideath activity from bovine liver and its identification as arginase: nitric oxide-independent inhibition of neuronal apoptosis. J Neurosci. 1998 Jun 01; 18(11):4083-95. PMID: 9592089.
        View in: PubMed
      225. Reeves JT, Rubin L. The pulmonary circulation: snapshots of progress. Am J Respir Crit Care Med. 1998 Apr; 157(4 Pt 2):S101-8. PMID: 9563768.
        View in: PubMed
      226. Yuan XJ, Wang J, Juhaszova M, Golovina VA, Rubin L. Molecular basis and function of voltage-gated K+ channels in pulmonary arterial smooth muscle cells. Am J Physiol. 1998 Apr; 274(4 Pt 1):L621-35. PMID: 9575881.
        View in: PubMed
      227. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin L. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet. 1998 Mar 07; 351(9104):726-7. PMID: 9504523.
        View in: PubMed
      228. Gaine SP, Rubin L. Medical and surgical treatment options for pulmonary hypertension. Am J Med Sci. 1998 Mar; 315(3):179-84. PMID: 9519930.
        View in: PubMed
      229. Plotkin JS, Kuo PC, Rubin L, Gaine S, Howell CD, Laurin J, Njoku MJ, Lim JW, Johnson LB. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation. 1998 Feb 27; 65(4):457-9. PMID: 9500616.
        View in: PubMed
      230. Zhao YJ, Wang J, Rubin L, Yuan XJ. Roles of K+ and Cl- channels in cAMP-induced pulmonary vasodilation. Exp Lung Res. 1998 Jan-Feb; 24(1):71-83. PMID: 9457470.
        View in: PubMed
      231. Wang J, Juhaszova M, Rubin L, Yuan XJ. Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest. 1997 Nov 01; 100(9):2347-53. PMID: 9410914; PMCID: PMC508432.
      232. Zhong J, Hwang TC, Adams HR, Rubin L. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol. 1997 Nov; 273(5 Pt 2):H2312-24. PMID: 9374768.
        View in: PubMed
      233. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, Rubin L. Distinctive clinical features of portopulmonary hypertension. Chest. 1997 Oct; 112(4):980-6. PMID: 9377962.
        View in: PubMed
      234. McCann UD, Seiden LS, Rubin L, Ricaurte GA. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. JAMA. 1997 Aug 27; 278(8):666-72. PMID: 9272900.
        View in: PubMed
      235. Zhong J, Adams HR, Rubin L. Cytosolic Ca2+ concentration and contraction-relaxation properties of ventricular myocytes from Escherichia coli endotoxemic guinea pigs: effect of fluid resuscitation. Shock. 1997 May; 7(5):383-8. PMID: 9165675.
        View in: PubMed
      236. Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin L, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Koch G, Li S, Clayton LM, Jöbsis MM, Blackburn SD, Crow JW, Long WA. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 1997 Mar 18; 95(6):1479-86. PMID: 9118516.
        View in: PubMed
      237. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin L. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation. 1997 Feb 27; 63(4):604-6. PMID: 9047158.
        View in: PubMed
      238. Zhao YJ, Wang J, Rubin L, Yuan XJ. Inhibition of K(V) and K(Ca) channels antagonizes NO-induced relaxation in pulmonary artery. Am J Physiol. 1997 Feb; 272(2 Pt 2):H904-12. PMID: 9124454.
        View in: PubMed
      239. Rubin L. Primary pulmonary hypertension. N Engl J Med. 1997 Jan 09; 336(2):111-7. PMID: 8988890.
        View in: PubMed
      240. Wang DX, Sheu SS, Sharma VK, Rubin L, Journet M, Kende AS, Abood LG. [3H]benzylpempidine, a new radioligand for probing a putative channel site on nicotinic cholinergic receptors. Life Sci. 1997; 60(15):1271-7. PMID: 9096244.
        View in: PubMed
      241. Yuan XJ, Bright RT, Aldinger AM, Rubin L. Nitric oxide inhibits serotonin-induced calcium release in pulmonary artery smooth muscle cells. Am J Physiol. 1997 Jan; 272(1 Pt 1):L44-50. PMID: 9038901.
        View in: PubMed
      242. Zhao YJ, Wang J, Tod ML, Rubin L, Yuan XJ. Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors. J Appl Physiol (1985). 1996 Dec; 81(6):2595-603. PMID: 9018511.
        View in: PubMed
      243. Rigden JP, Cornetta K, Srour EF, Hanna M, Broun ER, Hromas R, Baute J, Hilton J, Cox E, Rubin L, Gonin R, Tricot G. Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1996 Nov; 18(5):913-9. PMID: 8932845.
        View in: PubMed
      244. Yuan XJ, Tod ML, Rubin L, Blaustein MP. NO hyperpolarizes pulmonary artery smooth muscle cells and decreases the intracellular Ca2+ concentration by activating voltage-gated K+ channels. Proc Natl Acad Sci U S A. 1996 Sep 17; 93(19):10489-94. PMID: 8816828; PMCID: PMC38412.
      245. Rubin L. The renin-angiotensin system and the "lesser circulation". A role in cor pulmonale? Chest. 1996 Sep; 110(3):584-5. PMID: 8797391.
        View in: PubMed
      246. Barst RJ, Rubin L, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 01; 334(5):296-301. PMID: 8532025.
        View in: PubMed
      247. Yuan XJ, Sugiyama T, Goldman WF, Rubin L, Blaustein MP. A mitochondrial uncoupler increases KCa currents but decreases KV currents in pulmonary artery myocytes. Am J Physiol. 1996 Jan; 270(1 Pt 1):C321-31. PMID: 8772460.
        View in: PubMed
      248. Yuan XJ, Tod ML, Rubin L, Blaustein MP. Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Exp Physiol. 1995 Sep; 80(5):803-13. PMID: 8546869.
        View in: PubMed
      249. Bright RT, Salvaterra CG, Rubin L, Yuan XJ. Inhibition of glycolysis by 2-DG increases [Ca2+]i in pulmonary arterial smooth muscle cells. Am J Physiol. 1995 Aug; 269(2 Pt 1):L203-8. PMID: 7653581.
        View in: PubMed
      250. Rubin L. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol. 1995 Jan 19; 75(3):51A-54A. PMID: 7840055.
        View in: PubMed
      251. Yuan XJ, Tod ML, Rubin L, Blaustein MP. Inhibition of cytochrome P-450 reduces voltage-gated K+ currents in pulmonary arterial myocytes. Am J Physiol. 1995 Jan; 268(1 Pt 1):C259-70. PMID: 7840155.
        View in: PubMed
      252. Graier WF, Myers PR, Rubin L, Adams HR, Parker JL. Escherichia coli endotoxin inhibits agonist-mediated cytosolic Ca2+ mobilization and nitric oxide biosynthesis in cultured endothelial cells. Circ Res. 1994 Oct; 75(4):659-68. PMID: 7923612.
        View in: PubMed
      253. Barst RJ, Rubin L, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994 Sep 15; 121(6):409-15. PMID: 8053614.
        View in: PubMed
      254. Zhong J, Rubin L, Parker JL, Adams HR. Cardiodynamic response to Escherichia coli endotoxemia: effects of fluid resuscitation. Shock. 1994 Sep; 2(3):203-9. PMID: 7743351.
        View in: PubMed
      255. Yuan XJ, Tod ML, Rubin L, Blaustein MP. Deoxyglucose and reduced glutathione mimic effects of hypoxia on K+ and Ca2+ conductances in pulmonary artery cells. Am J Physiol. 1994 Jul; 267(1 Pt 1):L52-63. PMID: 8048542.
        View in: PubMed
      256. Salvaterra CG, Rubin L. Investigation and management of pulmonary hypertension in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993 Nov; 148(5):1414-7. PMID: 8239185.
        View in: PubMed
      257. Rubin L. Primary pulmonary hypertension. Chest. 1993 Jul; 104(1):236-50. PMID: 8325077.
        View in: PubMed
      258. Anderson DE, Yuan XJ, Tseng CM, Rubin L, Rosen GM, Tod ML. Nitrone spin-traps block calcium channels and induce pulmonary artery relaxation independent of free radicals. Biochem Biophys Res Commun. 1993 Jun 30; 193(3):878-85. PMID: 8391809.
        View in: PubMed
      259. Yuan XJ, Goldman WF, Tod ML, Rubin L, Blaustein MP. Ionic currents in rat pulmonary and mesenteric arterial myocytes in primary culture and subculture. Am J Physiol. 1993 Feb; 264(2 Pt 1):L107-15. PMID: 8447424.
        View in: PubMed
      260. Yuan XJ, Goldman WF, Tod ML, Rubin L, Blaustein MP. Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes. Am J Physiol. 1993 Feb; 264(2 Pt 1):L116-23. PMID: 8447425.
        View in: PubMed
      261. Tseng CM, Goodman LW, Rubin L, Tod ML. NG-monomethyl-L-arginine paradoxically relaxes preconstricted canine intrapulmonary arteries. J Appl Physiol (1985). 1993 Feb; 74(2):549-58. PMID: 8458770.
        View in: PubMed
      262. Khraishi M, Reis M, Berinstein N, Rubin L. Lymphadenopathy, oligoclonal T cell receptor rearrangement and systemic lupus erythematosus. J Rheumatol. 1992 Dec; 19(12):1966-9. PMID: 1294749.
        View in: PubMed
      263. Tod ML, Rubin L. Pulmonary vascular responses to thromboxane and prostacyclin. J Appl Physiol (1985). 1992 Dec; 73(6):2717-9. PMID: 1490991.
        View in: PubMed
      264. Tod ML, Yoshimura K, Rubin L. Ontogeny of neonatal pulmonary vascular pressure-flow relationships. Am J Physiol. 1992 Mar; 262(3 Pt 2):H684-90. PMID: 1558176.
        View in: PubMed
      265. Nall KC, Rubin L, Lipskind S, Sennesh JD. Reversible pulmonary hypertension associated with anorexigen use. Am J Med. 1991 Jul; 91(1):97-9. PMID: 1858837.
        View in: PubMed
      266. Tod ML, Yoshimura K, Rubin L. Indomethacin prevents ventilation-induced decreases in pulmonary vascular resistance of the middle region in fetal lambs. Pediatr Res. 1991 May; 29(5):449-54. PMID: 1910157.
        View in: PubMed
      267. Rubin L. New concepts in the treatment of primary pulmonary hypertension. Md Med J. 1991 Mar; 40(3):209-11. PMID: 2008166.
        View in: PubMed
      268. Tod ML, Yoshimura K, Rubin L. Pulmonary vascular distensibility of arterial, middle, and venous regions in newborn lambs. J Appl Physiol (1985). 1991 Mar; 70(3):1315-22. PMID: 2032998.
        View in: PubMed
      269. Salvaterra CG, Rubin L. Cardiovascular effects of pulmonary hypertension. Trends Cardiovasc Med. 1991 Mar; 1(2):65-9. PMID: 21239332.
        View in: PubMed
      270. Rubin L, Tod ML, Yoshimura K. Effects of nitrendipine and hypoxia on pulmonary vascular resistance in experimental emphysema. Am Rev Respir Dis. 1990 Sep; 142(3):625-30. PMID: 2389915.
        View in: PubMed
      271. Yuan XJ, Tod ML, Rubin L, Blaustein MP. Contrasting effects of hypoxia on tension in rat pulmonary and mesenteric arteries. Am J Physiol. 1990 Aug; 259(2 Pt 2):H281-9. PMID: 2117400.
        View in: PubMed
      272. Rubin L, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990 Apr 01; 112(7):485-91. PMID: 2107780.
        View in: PubMed
      273. Weir EK, Rubin L, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Elliott CG, Fishman AP, Goldring RM, Groves BM. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis. 1989 Dec; 140(6):1623-30. PMID: 2690706.
        View in: PubMed
      274. Yoshimura K, Tod ML, Pier KG, Rubin L. Effects of a thromboxane A2 analogue and prostacyclin on lung fluid balance in newborn lambs. Circ Res. 1989 Nov; 65(5):1409-16. PMID: 2509097.
        View in: PubMed
      275. Rubin L. Approach to the diagnosis and treatment of pulmonary hypertension. Chest. 1989 Sep; 96(3):659-64. PMID: 2766828.
        View in: PubMed
      276. Lieberburg I, Spinner N, Snyder S, Anderson J, Goldgaber D, Smulowitz M, Carroll Z, Emanuel B, Breitner J, Rubin L. Cloning of a cDNA encoding the rat high molecular weight neurofilament peptide (NF-H): developmental and tissue expression in the rat, and mapping of its human homologue to chromosomes 1 and 22. Proc Natl Acad Sci U S A. 1989 Apr; 86(7):2463-7. PMID: 2928342; PMCID: PMC286933.
      277. Salvaterra CG, Rubin L, Schaeffer J, Blaustein MP. The influence of the transmembrane sodium gradient on the responses of pulmonary arteries to decreases in oxygen tension. Am Rev Respir Dis. 1989 Apr; 139(4):933-9. PMID: 2539035.
        View in: PubMed
      278. Yoshimura K, Tod ML, Pier KG, Rubin L. Role of venoconstriction in thromboxane-induced pulmonary hypertension and edema in lambs. J Appl Physiol (1985). 1989 Feb; 66(2):929-35. PMID: 2651387.
        View in: PubMed
      279. Silverman HJ, Abrams J, Rubin L. Effects of interleukin-2 on oxygen delivery and consumption in patients with advanced malignancy. Chest. 1988 Oct; 94(4):816-21. PMID: 3262489.
        View in: PubMed
      280. Rubin L. Primary pulmonary hypertension. Chest. 1988 Apr; 93(4):894-5. PMID: 3280265.
        View in: PubMed
      281. Long WA, Rubin L. Prostacyclin and PGE1 treatment of pulmonary hypertension. Am Rev Respir Dis. 1987 Sep; 136(3):773-6. PMID: 3307575.
        View in: PubMed
      282. Rubin L, Windberg P, Taylor W, Heatfield B. Pulmonary vascular structural and functional changes in papain-induced emphysema in dogs. Am Rev Respir Dis. 1987 Sep; 136(3):704-9. PMID: 3631741.
        View in: PubMed
      283. Johnson RA, Rubin L. Noninvasive evaluation of right ventricular function. Clin Chest Med. 1987 Mar; 8(1):65-80. PMID: 3552388.
        View in: PubMed
      284. Rubin L. Vasodilators and pulmonary hypertension: where do we go from here? Am Rev Respir Dis. 1987 Feb; 135(2):287. PMID: 3813188.
        View in: PubMed
      285. Bassuk EL, Rubin L, Lauriat AS. Characteristics of sheltered homeless families. Am J Public Health. 1986 Sep; 76(9):1097-101. PMID: 3740332; PMCID: PMC1646563.
      286. Peil ML, Rubin L. Therapy of secondary pulmonary hypertension. Heart Lung. 1986 Sep; 15(5):450-6. PMID: 3639073.
        View in: PubMed
      287. Peil ML, Rubin L. Oxygen therapy titrated to raise mixed venous oxygen content in COPD. Chest. 1986 Mar; 89(3):343-7. PMID: 3948546.
        View in: PubMed
      288. Dal Nogare AR, Rubin L. The effects of hydralazine on exercise capacity in pulmonary hypertension secondary to chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986 Mar; 133(3):385-9. PMID: 3954247.
        View in: PubMed
      289. Hughes JD, Rubin L. Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature. Medicine (Baltimore). 1986 Jan; 65(1):56-72. PMID: 2867454.
        View in: PubMed
      290. Groves BM, Rubin L, Frosolono MF, Cato AE, Reeves JT. A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. Am Heart J. 1985 Dec; 110(6):1200-4. PMID: 3907315.
        View in: PubMed
      291. Rubin L. Calcium channel blockers in primary pulmonary hypertension. Chest. 1985 Oct; 88(4 Suppl):257S-260S. PMID: 4042732.
        View in: PubMed
      292. Rubin L. Pulmonary thromboembolic disease--diagnosis, management and prevention. Am J Med Sci. 1985 Oct; 290(4):167-77. PMID: 4073115.
        View in: PubMed
      293. Rubin L, Hughes JD, Lazar JD. The effects of eicosanoid synthesis inhibitors on normoxic and hypoxic pulmonary vascular tone in dogs. Am Rev Respir Dis. 1985 Jul; 132(1):93-8. PMID: 3925829.
        View in: PubMed
      294. Ensley RD, Rubin L. Nafazatrom (Bay g 6575) blunts canine hypoxic pulmonary vasoconstriction: evidence for a prostaglandin-mediated mechanism. Prostaglandins Leukot Med. 1985 Apr; 18(1):95-104. PMID: 3923499.
        View in: PubMed
      295. Bassuk EL, Rubin L, Lauriat A. Is homelessness a mental health problem? Am J Psychiatry. 1984 Dec; 141(12):1546-50. PMID: 6209990.
        View in: PubMed
      296. Hughes JD, Rubin L. Relation between mixed venous oxygen tension and pulmonary vascular tone during normoxic, hyperoxic and hypoxic ventilation in dogs. Am J Cardiol. 1984 Nov 01; 54(8):1118-23. PMID: 6496333.
        View in: PubMed
      297. Rubin L, Urowitz MB, Pruzanski W. Systemic lupus erythematosus with paraproteinemia. Arthritis Rheum. 1984 Jun; 27(6):638-44. PMID: 6610425.
        View in: PubMed
      298. Rubin L, Nolte JF. Modulation of the response of a photosensitive muscle by beta-adrenergic regulation of cyclic AMP levels. Nature. 1984 Feb 9-15; 307(5951):551-3. PMID: 6141528.
        View in: PubMed
      299. Miller MJ, Chappell TR, Cook W, De Olazabal JR, Rubin L. Effects of oral hydralazine on gas exchange in patients with cor pulmonale. Am J Med. 1983 Dec; 75(6):937-42. PMID: 6650548.
        View in: PubMed
      300. Rubin L, Nicod P, Hillis LD, Firth BG. Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. Ann Intern Med. 1983 Oct; 99(4):433-8. PMID: 6625374.
        View in: PubMed
      301. Henrich WL, Woodard TD, Meyer BD, Chappell TR, Rubin L. High sodium bicarbonate and acetate hemodialysis: double-blind crossover comparison of hemodynamic and ventilatory effects. Kidney Int. 1983 Aug; 24(2):240-5. PMID: 6314029.
        View in: PubMed
      302. Cohen MD, Rubin L, Taylor WE, Cuthbert JA. Primary pulmonary hypertension: an unusual case associated with extrahepatic portal hypertension. Hepatology. 1983 Jul-Aug; 3(4):588-92. PMID: 6862372.
        View in: PubMed
      303. Chappell TR, Rubin L, Markham RV, Firth BG. Independence of oxygen consumption and systemic oxygen transport in patients with either stable pulmonary hypertension or refractory left ventricular failure. Am Rev Respir Dis. 1983 Jul; 128(1):30-3. PMID: 6870066.
        View in: PubMed
      304. Rubin L, Lazar JD. Nonadrenergic effects of isoproterenol in dogs with hypoxic pulmonary vasoconstriction. Possible role of prostaglandins. J Clin Invest. 1983 May; 71(5):1366-74. PMID: 6406548; PMCID: PMC437000.
      305. Rubin L. Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension. Clin Chest Med. 1983 May; 4(2):309-19. PMID: 6342925.
        View in: PubMed
      306. Rubin L, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982 Aug; 66(2):334-8. PMID: 7046988.
        View in: PubMed
      307. Rubin L, Handel F, Peter RH. The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure. Circulation. 1982 Jun; 65(7):1369-73. PMID: 7074795.
        View in: PubMed
      308. Rubin L, Lazar JD. Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction. J Clin Invest. 1981 Jan; 67(1):193-200. PMID: 7451649; PMCID: PMC371587.
      309. Rubin L, Peter RH. Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. Am J Cardiol. 1981 Jan; 47(1):116-22. PMID: 7457397.
        View in: PubMed
      310. Rubin L, Peter RH. Primary pulmonary hypertension: new approaches to therapy. Am Heart J. 1980 Nov; 100(5):757-9. PMID: 7446372.
        View in: PubMed
      311. Rubin L, Peter RH. Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med. 1980 Jan 10; 302(2):69-73. PMID: 7350435.
        View in: PubMed
      312. Rubin L, Katz RS. Letter: Nurse practitioners. Ann Intern Med. 1975 Aug; 83(2):278-9. PMID: 1147467.
        View in: PubMed